eli lilly and company retatrutide A Study of (LY3437943) in Participants With Obesity Cardiovascular Disease (TRIUMPH-3) New GLP-1 obesity drug, retatrutide,

The products include high-protein frozen meals, protein-rich snacks, and portion-controlled options formulated to help GLP-1 medication users meet their nutritional needs while eating significantly less food

These drugs, widely used for diabetes management and weight loss, have been linked by plaintiffs to serious conditions such as gastroparesis, severe vomiting, and bowel obstruction

Understanding and discussing these side effects with healthcare providers is essential

Every 5 kg of weight loss independently reduces systolic blood pressure by approximately 3 to 5 mmHg, reduces triglycerides, improves HDL cholesterol, reduces insulin resistance, decreases systemic inflammation, and reduces mechanical strain on the heart